The traditional pattern of Japanese firms outlicensing their products for the West is shifting as the U.S. market looks increasingly appealing compared to Japan’s price controls and sagging economy. Major Japanese pharmas have been building U.S. development capability, resulting in a full pipeline of products to be developed and marketed directly in the U.S.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.
Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
